Login to Your Account

22 Years Later

Twilight of ESA Monopoly as New Anemia Options Advance

By Trista Morrison

Monday, December 19, 2011

For more than 20 years, erythropoiesis-stimulating agents (ESAs) have dominated the anemia field. But this month's advisory committee win by Affymax Inc.'s peginesatide, as well as new data coming out of the American Society of Nephrology's Kidney Week and the American Society of Hematology's annual meeting, indicate big changes are afoot – changes that impact competitors not only in the ESA space but in the iron-replacement space as well.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription